Copyright Reports & Markets. All rights reserved.

Global Opioid Induced Constipation Drugs Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Opioid Induced Constipation Drugs Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Opioid Induced Constipation Drugs Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Lubiprostone
    • 1.4.3 Methyl Naltrexone Bromide
    • 1.4.4 Naldemedine
    • 1.4.5 Alvimopan
    • 1.4.6 Other
  • 1.5 Market by Application
    • 1.5.1 Global Opioid Induced Constipation Drugs Market Share by Application: 2020 VS 2026
    • 1.5.2 Hospital Pharmacies
    • 1.5.3 Retail Pharmacies
    • 1.5.4 Online Pharmacies
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Global Growth Trends

  • 2.1 Global Opioid Induced Constipation Drugs Market Perspective (2015-2026)
  • 2.2 Global Opioid Induced Constipation Drugs Growth Trends by Regions
    • 2.2.1 Opioid Induced Constipation Drugs Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Opioid Induced Constipation Drugs Historic Market Share by Regions (2015-2020)
    • 2.2.3 Opioid Induced Constipation Drugs Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Opioid Induced Constipation Drugs Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Opioid Induced Constipation Drugs Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Opioid Induced Constipation Drugs Players by Market Size
    • 3.1.1 Global Top Opioid Induced Constipation Drugs Players by Revenue (2015-2020)
    • 3.1.2 Global Opioid Induced Constipation Drugs Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Opioid Induced Constipation Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Opioid Induced Constipation Drugs Market Concentration Ratio
    • 3.2.1 Global Opioid Induced Constipation Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Opioid Induced Constipation Drugs Revenue in 2019
  • 3.3 Opioid Induced Constipation Drugs Key Players Head office and Area Served
  • 3.4 Key Players Opioid Induced Constipation Drugs Product Solution and Service
  • 3.5 Date of Enter into Opioid Induced Constipation Drugs Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Opioid Induced Constipation Drugs Historic Market Size by Type (2015-2020)
  • 4.2 Global Opioid Induced Constipation Drugs Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

  • 5.1 Global Opioid Induced Constipation Drugs Market Size by Application (2015-2020)
  • 5.2 Global Opioid Induced Constipation Drugs Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Opioid Induced Constipation Drugs Market Size (2015-2020)
  • 6.2 Opioid Induced Constipation Drugs Key Players in North America (2019-2020)
  • 6.3 North America Opioid Induced Constipation Drugs Market Size by Type (2015-2020)
  • 6.4 North America Opioid Induced Constipation Drugs Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Opioid Induced Constipation Drugs Market Size (2015-2020)
  • 7.2 Opioid Induced Constipation Drugs Key Players in Europe (2019-2020)
  • 7.3 Europe Opioid Induced Constipation Drugs Market Size by Type (2015-2020)
  • 7.4 Europe Opioid Induced Constipation Drugs Market Size by Application (2015-2020)

8 China

  • 8.1 China Opioid Induced Constipation Drugs Market Size (2015-2020)
  • 8.2 Opioid Induced Constipation Drugs Key Players in China (2019-2020)
  • 8.3 China Opioid Induced Constipation Drugs Market Size by Type (2015-2020)
  • 8.4 China Opioid Induced Constipation Drugs Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Opioid Induced Constipation Drugs Market Size (2015-2020)
  • 9.2 Opioid Induced Constipation Drugs Key Players in Japan (2019-2020)
  • 9.3 Japan Opioid Induced Constipation Drugs Market Size by Type (2015-2020)
  • 9.4 Japan Opioid Induced Constipation Drugs Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Opioid Induced Constipation Drugs Market Size (2015-2020)
  • 10.2 Opioid Induced Constipation Drugs Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Opioid Induced Constipation Drugs Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Opioid Induced Constipation Drugs Market Size by Application (2015-2020)

11 India

  • 11.1 India Opioid Induced Constipation Drugs Market Size (2015-2020)
  • 11.2 Opioid Induced Constipation Drugs Key Players in India (2019-2020)
  • 11.3 India Opioid Induced Constipation Drugs Market Size by Type (2015-2020)
  • 11.4 India Opioid Induced Constipation Drugs Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Opioid Induced Constipation Drugs Market Size (2015-2020)
  • 12.2 Opioid Induced Constipation Drugs Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Opioid Induced Constipation Drugs Market Size by Type (2015-2020)
  • 12.4 Central & South America Opioid Induced Constipation Drugs Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Ironwood Pharmaceuticals Inc
    • 13.1.1 Ironwood Pharmaceuticals Inc Company Details
    • 13.1.2 Ironwood Pharmaceuticals Inc Business Overview
    • 13.1.3 Ironwood Pharmaceuticals Inc Opioid Induced Constipation Drugs Introduction
    • 13.1.4 Ironwood Pharmaceuticals Inc Revenue in Opioid Induced Constipation Drugs Business (2015-2020))
    • 13.1.5 Ironwood Pharmaceuticals Inc Recent Development
  • 13.2 Daiichi Sankyo Co Ltd
    • 13.2.1 Daiichi Sankyo Co Ltd Company Details
    • 13.2.2 Daiichi Sankyo Co Ltd Business Overview
    • 13.2.3 Daiichi Sankyo Co Ltd Opioid Induced Constipation Drugs Introduction
    • 13.2.4 Daiichi Sankyo Co Ltd Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
    • 13.2.5 Daiichi Sankyo Co Ltd Recent Development
  • 13.3 Pfizer
    • 13.3.1 Pfizer Company Details
    • 13.3.2 Pfizer Business Overview
    • 13.3.3 Pfizer Opioid Induced Constipation Drugs Introduction
    • 13.3.4 Pfizer Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
    • 13.3.5 Pfizer Recent Development
  • 13.4 Progenics Pharmaceuticals Inc
    • 13.4.1 Progenics Pharmaceuticals Inc Company Details
    • 13.4.2 Progenics Pharmaceuticals Inc Business Overview
    • 13.4.3 Progenics Pharmaceuticals Inc Opioid Induced Constipation Drugs Introduction
    • 13.4.4 Progenics Pharmaceuticals Inc Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
    • 13.4.5 Progenics Pharmaceuticals Inc Recent Development
  • 13.5 Shionogi & Co., Ltd
    • 13.5.1 Shionogi & Co., Ltd Company Details
    • 13.5.2 Shionogi & Co., Ltd Business Overview
    • 13.5.3 Shionogi & Co., Ltd Opioid Induced Constipation Drugs Introduction
    • 13.5.4 Shionogi & Co., Ltd Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
    • 13.5.5 Shionogi & Co., Ltd Recent Development
  • 13.6 Allergan Plc
    • 13.6.1 Allergan Plc Company Details
    • 13.6.2 Allergan Plc Business Overview
    • 13.6.3 Allergan Plc Opioid Induced Constipation Drugs Introduction
    • 13.6.4 Allergan Plc Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
    • 13.6.5 Allergan Plc Recent Development
  • 13.7 Nektar Therapeutics
    • 13.7.1 Nektar Therapeutics Company Details
    • 13.7.2 Nektar Therapeutics Business Overview
    • 13.7.3 Nektar Therapeutics Opioid Induced Constipation Drugs Introduction
    • 13.7.4 Nektar Therapeutics Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
    • 13.7.5 Nektar Therapeutics Recent Development
  • 13.8 Purdue Pharma
    • 13.8.1 Purdue Pharma Company Details
    • 13.8.2 Purdue Pharma Business Overview
    • 13.8.3 Purdue Pharma Opioid Induced Constipation Drugs Introduction
    • 13.8.4 Purdue Pharma Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
    • 13.8.5 Purdue Pharma Recent Development
  • 13.9 S.L.A. Pharma AG
    • 13.9.1 S.L.A. Pharma AG Company Details
    • 13.9.2 S.L.A. Pharma AG Business Overview
    • 13.9.3 S.L.A. Pharma AG Opioid Induced Constipation Drugs Introduction
    • 13.9.4 S.L.A. Pharma AG Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
    • 13.9.5 S.L.A. Pharma AG Recent Development
  • 13.10 Mundipharma International Limited
    • 13.10.1 Mundipharma International Limited Company Details
    • 13.10.2 Mundipharma International Limited Business Overview
    • 13.10.3 Mundipharma International Limited Opioid Induced Constipation Drugs Introduction
    • 13.10.4 Mundipharma International Limited Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
    • 13.10.5 Mundipharma International Limited Recent Development
  • 13.11 Ono Pharmaceutical Co., Ltd
    • 10.11.1 Ono Pharmaceutical Co., Ltd Company Details
    • 10.11.2 Ono Pharmaceutical Co., Ltd Business Overview
    • 10.11.3 Ono Pharmaceutical Co., Ltd Opioid Induced Constipation Drugs Introduction
    • 10.11.4 Ono Pharmaceutical Co., Ltd Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
    • 10.11.5 Ono Pharmaceutical Co., Ltd Recent Development
  • 13.12 Takeda Pharmaceutical Company Limited
    • 10.12.1 Takeda Pharmaceutical Company Limited Company Details
    • 10.12.2 Takeda Pharmaceutical Company Limited Business Overview
    • 10.12.3 Takeda Pharmaceutical Company Limited Opioid Induced Constipation Drugs Introduction
    • 10.12.4 Takeda Pharmaceutical Company Limited Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
    • 10.12.5 Takeda Pharmaceutical Company Limited Recent Development
  • 13.13 Theravance Biopharma Inc
    • 10.13.1 Theravance Biopharma Inc Company Details
    • 10.13.2 Theravance Biopharma Inc Business Overview
    • 10.13.3 Theravance Biopharma Inc Opioid Induced Constipation Drugs Introduction
    • 10.13.4 Theravance Biopharma Inc Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
    • 10.13.5 Theravance Biopharma Inc Recent Development
  • 13.14 Bausch Health
    • 10.14.1 Bausch Health Company Details
    • 10.14.2 Bausch Health Business Overview
    • 10.14.3 Bausch Health Opioid Induced Constipation Drugs Introduction
    • 10.14.4 Bausch Health Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
    • 10.14.5 Bausch Health Recent Development
  • 13.15 Cosmo Pharmaceuticals SA
    • 10.15.1 Cosmo Pharmaceuticals SA Company Details
    • 10.15.2 Cosmo Pharmaceuticals SA Business Overview
    • 10.15.3 Cosmo Pharmaceuticals SA Opioid Induced Constipation Drugs Introduction
    • 10.15.4 Cosmo Pharmaceuticals SA Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
    • 10.15.5 Cosmo Pharmaceuticals SA Recent Development
  • 13.16 Daewoong Pharmaceutical
    • 10.16.1 Daewoong Pharmaceutical Company Details
    • 10.16.2 Daewoong Pharmaceutical Business Overview
    • 10.16.3 Daewoong Pharmaceutical Opioid Induced Constipation Drugs Introduction
    • 10.16.4 Daewoong Pharmaceutical Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
    • 10.16.5 Daewoong Pharmaceutical Recent Development
  • 13.17 C.B. Fleet Company
    • 10.17.1 C.B. Fleet Company Company Details
    • 10.17.2 C.B. Fleet Company Business Overview
    • 10.17.3 C.B. Fleet Company Opioid Induced Constipation Drugs Introduction
    • 10.17.4 C.B. Fleet Company Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
    • 10.17.5 C.B. Fleet Company Recent Development
  • 13.18 Sucampo Pharmaceuticals
    • 10.18.1 Sucampo Pharmaceuticals Company Details
    • 10.18.2 Sucampo Pharmaceuticals Business Overview
    • 10.18.3 Sucampo Pharmaceuticals Opioid Induced Constipation Drugs Introduction
    • 10.18.4 Sucampo Pharmaceuticals Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
    • 10.18.5 Sucampo Pharmaceuticals Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    Opioid Induced Constipation Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Opioid Induced Constipation Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    The key players covered in this study
    Ironwood Pharmaceuticals Inc
    Daiichi Sankyo Co Ltd
    Pfizer
    Progenics Pharmaceuticals Inc
    Shionogi & Co., Ltd
    Allergan Plc
    Nektar Therapeutics
    Purdue Pharma
    S.L.A. Pharma AG
    Mundipharma International Limited
    Ono Pharmaceutical Co., Ltd
    Takeda Pharmaceutical Company Limited
    Theravance Biopharma Inc
    Bausch Health
    Cosmo Pharmaceuticals SA
    Daewoong Pharmaceutical
    C.B. Fleet Company
    Sucampo Pharmaceuticals

    Market segment by Type, the product can be split into
    Lubiprostone
    Methyl Naltrexone Bromide
    Naldemedine
    Alvimopan
    Other
    Market segment by Application, split into
    Hospital Pharmacies
    Retail Pharmacies
    Online Pharmacies

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    Buy now